Liquidia to Present at Upcoming Investor Conferences

Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company's primary focus includes the development and commercialization of products for pulmonary hypertension and other applications of its proprietary PRINT® Technology [3] - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, which is an investigational drug for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and markets generic Treprostinil Injection for PAH treatment [3] Upcoming Events - Liquidia Corporation will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024, from 11:00 – 11:35 a.m. ET [1] - The company will also present at the 2024 Cantor Global Healthcare Conference in New York on September 19, 2024, from 1:30 – 1:50 p.m. ET [1] - Access to the webcasts of these presentations will be available on Liquidia's website [1] Additional Information - An archived version of each presentation will be available on Liquidia's website for at least 30 days following the events [2]